Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.64 |
| ▸ | PI4KA | P42356 | 2/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21943144 | 0.81 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL10889158 | 0.80 | ADORA2A (0.68) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11254072 | 0.80 | ADORA2A (0.70) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14190719 | 0.79 | ADORA2A (0.66) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12825351 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2116000 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7832523 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1924594 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL455646 | 0.77 | P2RX7 (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL7812370 | 0.76 | ADORA2A (0.63) | ADORA2AADORA1ADORA2BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | Epizyme, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-1631260-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004078163-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0073490-B1 | DIHYDROTHIAZOLE-PURINES | Newport Pharmaceuticals International, Inc. (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4510144-A | Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives | NEWPORT PHARMACEUTICALS INTERNATIONAL (US) | 1985-04-09 | — | — | US | disclosed |
| US-4387226-A | VIRICIDES, IMMUNOLOGY | NEWPORT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 1983-06-07 | — | — | US | disclosed |
| EP-0073490-A1 | Dihydrothiazole-purines | Newport Pharmaceuticals International, Inc. (US) | 1983-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300562-A1 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS | DOT1L, MECP2, TDP1 | ADORA2A 210/4885ADORA1 80/4885PI4KA 3857/4885 |
| US-10968247-B2 | Methods of synthesizing substituted purine compounds | DOT1L, MECP2, TDP1 | ADORA2A 210/4885ADORA1 80/4885PI4KA 3857/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA2A 73/4885ADORA1 32/4885PI4KA 2270/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | ADORA2A 182/4885ADORA1 186/4885PI4KA 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.